

# Andrew J Innes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7621219/publications.pdf>

Version: 2024-02-01

28  
papers

1,673  
citations

759233

12  
h-index

552781

26  
g-index

29  
all docs

29  
docs citations

29  
times ranked

3013  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	1.3	1
2	Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2022, 197, .	2.5	13
3	Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms. <i>Clinical Infectious Diseases</i> , 2021, 72, 1444-1447.	5.8	40
4	Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm. <i>Leukemia</i> , 2021, 35, 2424-2430.	7.2	8
5	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 684659.	3.9	14
6	TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 346-355.	2.5	18
7	Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial. <i>Blood</i> , 2021, 138, 4200-4200.	1.4	0
8	Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality. <i>Leukemia</i> , 2020, 34, 667-670.	7.2	10
9	Evidence for HIV-1 cure after CCR5 <sup>Δ32/Δ32</sup> allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. <i>Lancet HIV</i> , 2020, 7, e340-e347.	4.7	151
10	Ruxolitinib for tocilizumab-refractory severe COVID-19 infection. <i>British Journal of Haematology</i> , 2020, 190, e198-e200.	2.5	37
11	Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2020, 136, 20-20.	1.4	6
12	Towards a Better Understanding of Cohesin Mutations in AML. <i>Frontiers in Oncology</i> , 2019, 9, 867.	2.8	26
13	HIV-1 remission following CCR5 <sup>Δ32/Δ32</sup> haematopoietic stem-cell transplantation. <i>Nature</i> , 2019, 568, 244-248.	27.8	447
14	Cardiac glycosides are broad-spectrum senolytics. <i>Nature Metabolism</i> , 2019, 1, 1074-1088.	11.9	207
15	Impact of route and adequacy of nutritional intake on outcomes of Allogeneic haematopoietic cell transplantation for haematologic malignancies. <i>Clinical Nutrition</i> , 2019, 38, 738-744.	5.0	37
16	C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early and long-term mortality. <i>British Journal of Haematology</i> , 2018, 180, 889-892.	2.5	6
17	BK-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2017, 98, 632-634.	2.2	36
18	Immunosuppression-associated Kaposi sarcoma following stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 9-9.	2.5	2

#	ARTICLE	IF	CITATIONS
19	Red cell fragments can mask severe thrombocytopenia. <i>Blood</i> , 2017, 130, 1484-1484.	1.4	4
20	Allogeneic transplantation for CML in the TKI era: striking the right balance. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 79-91.	27.6	38
21	Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Blood</i> , 2016, 128, 2226-2226.	1.4	1
22	Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation. <i>Blood</i> , 2016, 128, 5726-5726.	1.4	3
23	Microbial Contamination of Haematopoietic Stem Cell Products: A Single Centre Experience. <i>Blood</i> , 2016, 128, 5741-5741.	1.4	2
24	The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions. <i>Blood</i> , 2016, 128, 5987-5987.	1.4	1
25	Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3411-3411.	1.4	0
26	mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. <i>Nature Cell Biology</i> , 2015, 17, 1205-1217.	10.3	552
27	Chronic Myeloid Leukemia—Transplantation in the Tyrosine Kinase Era. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1037-1053.	2.2	12
28	Unexpected pancytopenia following treatment of acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 412-412.	4.1	1